Wilms’ Tumor (Nephroblastoma) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Wilms' Tumor (Nephroblastoma) – Pipeline Review, H2 2016’, provides an overview of the Wilms' Tumor (Nephroblastoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wilms' Tumor (Nephroblastoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wilms' Tumor (Nephroblastoma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Wilms' Tumor (Nephroblastoma)

The report reviews pipeline therapeutics for Wilms' Tumor (Nephroblastoma) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Wilms' Tumor (Nephroblastoma) therapeutics and enlists all their major and minor projects

The report assesses Wilms' Tumor (Nephroblastoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Wilms' Tumor (Nephroblastoma)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Wilms' Tumor (Nephroblastoma)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Wilms' Tumor (Nephroblastoma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Exelixis Inc

NanoSmart Pharmaceuticals Inc

Recombio SL

Selvita SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Wilms' Tumor (Nephroblastoma) Overview 6

Therapeutics Development 7

Pipeline Products for Wilms' Tumor (Nephroblastoma) - Overview 7

Pipeline Products for Wilms' Tumor (Nephroblastoma) - Comparative Analysis 8

Wilms' Tumor (Nephroblastoma) - Therapeutics under Development by Companies 9

Wilms' Tumor (Nephroblastoma) - Therapeutics under Investigation by Universities/Institutes 10

Wilms' Tumor (Nephroblastoma) - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Wilms' Tumor (Nephroblastoma) - Products under Development by Companies 13

Wilms' Tumor (Nephroblastoma) - Products under Investigation by Universities/Institutes 14

Wilms' Tumor (Nephroblastoma) - Companies Involved in Therapeutics Development 15

Exelixis Inc 15

NanoSmart Pharmaceuticals Inc 16

Recombio SL 17

Selvita SA 18

Wilms' Tumor (Nephroblastoma) - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

cabozantinib s-malate - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Cellular Immunotherapy for Oncology - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Monoclonal Antibody Conjugate for Wilms' Tumor - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

racotumomab - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

SEL-12034 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Wilms' Tumor (Nephroblastoma) - Dormant Projects 52

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2016 7

Number of Products under Development for Wilms' Tumor (Nephroblastoma) – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Wilms' Tumor (Nephroblastoma) – Pipeline by Exelixis Inc, H2 2016 15

Wilms' Tumor (Nephroblastoma) – Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016 16

Wilms' Tumor (Nephroblastoma) – Pipeline by Recombio SL, H2 2016 17

Wilms' Tumor (Nephroblastoma) – Pipeline by Selvita SA, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Wilms' Tumor (Nephroblastoma) – Dormant Projects, H2 2016 52

List of Figures

List of Figures

Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2016 7

Number of Products under Development for Wilms' Tumor (Nephroblastoma) – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Top 10 Targets, H2 2016 20

Number of Products by Stage and Top 10 Targets, H2 2016 20

Number of Products by Top 10 Mechanism of Actions, H2 2016 22

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports